Results 241 to 250 of about 133,463 (299)

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN

Cancer Science, EarlyView.
In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Tetsuya Mitsudomi, John V. Heymach, Yoshitsugu Horio, Fumihiro Tanaka, Hiroshi Tanaka, Shoichi Kuyama, Morihito Okada, Shinichi Toyooka, Yasutaka Watanabe, Martin Reck, David Harpole, Janis M. Taube, Yuka Olivo, Huiling Xiong, Tamer M. Fouad, Allen Chen, Hiroaki Akamatsu   +16 more
wiley   +1 more source

Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in <i>MTAP</i>-Null Non-Small Cell Lung Cancer. [PDF]

Biomolecules
Fu R, Wang Y, Rehman I, Bedford E, Sharif S, Nguyen ND, Powell RT, Adams A, Liu W, Wang S, He W, Lu Y, Liu B, Shah PA, Ahnert JR, Chen T, Peng W, Stephan CC, Liu X, Bedford MT, Xu H.   +20 more
europepmc   +1 more source

MEK inhibitor retinopathy

Annals of Oncology, 2017
openaire   +1 more source

Disseminated Xanthogranuloma Harboring a GAB2::BRAF Fusion and MITF Pathogenic Variant Successfully Treated With Cobimetinib: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Several activating mutations and gene fusions involving the mitogen‐activated protein kinase (MAPK) pathway have appeared in the literature regarding histiocytic neoplasms. We identified a GAB2::BRAF fusion in a cutaneous lesion of a 36‐year‐old male who developed central diabetes insipidus and reddish‐pink grouped papules on the bilateral ...
Pauline C. Xu, Allison M. Cushman‐Vokoun, Christopher R. D’Angelo, Dinesh Pradhan   +3 more
wiley   +1 more source

WISP-3 promotes tumor-monocyte adhesion through a MEK/ERK-dependent miR-12131/ICAM-4 axis in lung adenocarcinoma. [PDF]

Int J Med Sci
Chao CC, Lin SL, Chen YC, Cheng CY, Chang EM, Tang CH, Lin CY.   +6 more
europepmc   +1 more source

MEK/ERK-Mediated Transcriptional Repression of Metabolic Genes Confers Host Defense Against <i>Gallid alphaherpesvirus 1</i> Infection via Modulating Fos Nuclear Translocation. [PDF]

Microorganisms
Cui L, Zhang Y, Zhang H, Feng S, Zhu Y, Li X, Liu P, Liu S, Li H.   +8 more
europepmc   +1 more source

Correction to "Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma". [PDF]

Mol Oncol
europepmc   +1 more source

Quantitative systems pharmacology modeling of class I-III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design. [PDF]

iScience
Hu J, Rao Q, Li Z, Li G, Bi Z, Wen D, Zhao C, Zhou G.   +7 more
europepmc   +1 more source

Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report. [PDF]

Case Rep Pediatr
Brown G, McNab S, Keogh S, Massie J, Eastaugh L, Pathmanathan L, Bertinetti M, Sullivan M, Orme L, Cloney T, Brown NJ, Tan TY, Quin R, Pertile M, Moon A, Bekhit E, Penington T.   +16 more
europepmc   +1 more source